<DOC>
	<DOCNO>NCT00751517</DOCNO>
	<brief_summary>The Systemic Necrotizing Vasculitides ( SNV ) encompass group rare diseases include Wegener 's Granulomatosis ( WG ) , Churg-Strauss Syndrome ( CSS ) , Microscopic polyangiitis ( MPA ) Polyarteritis nodosa ( PAN ) . Common histological finding inflammation fibrinoid necrosis small vessel sporadic absent immune-deposits . The gold standard therapy SNV currently represent association Cyclophosphamide Prednisone . The limit approach high frequency recurrent disease increase incidence malignancy infection . The aim present study compare efficacy Methotrexate v Cyclophosphamide Remission Maintenance SNV .</brief_summary>
	<brief_title>Cyclophosphamide Versus Methotrexate Remission Maintenance Systemic Necrotizing Vasculitides</brief_title>
	<detailed_description />
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Polyarteritis Nodosa</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis clinically active SNV Lifeexpectancy &gt; 1 year Written inform consent Creatinine clearance &lt; 10 ml/min/1.73 mq Aminotransferase level twice upper limit normal range HBsAg positivity antiHCV Ig HCVRNA positivity HIV positivity Active malignancy Coexistence connective tissue disease Prednisolone , cyclophosphamide methotrexate hypersensitivity Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Vasculitis</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Systemic Necrotizing Vasculitides</keyword>
</DOC>